Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Equity (2022 - 2025)

Historic Return on Equity for InMed Pharmaceuticals (INM) over the last 4 years, with Q3 2025 value amounting to 0.66%.

  • InMed Pharmaceuticals' Return on Equity rose 1200.0% to 0.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.66%, marking a year-over-year increase of 1200.0%. This contributed to the annual value of 0.72% for FY2025, which is 0.0% changed from last year.
  • Per InMed Pharmaceuticals' latest filing, its Return on Equity stood at 0.66% for Q3 2025, which was up 1200.0% from 0.8% recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Return on Equity peaked at 0.51% during Q1 2024, and registered a low of 5.55% during Q3 2023.
  • Over the past 4 years, InMed Pharmaceuticals' median Return on Equity value was 1.12% (recorded in 2023), while the average stood at 1.59%.
  • Its Return on Equity has fluctuated over the past 5 years, first plummeted by -36400bps in 2023, then skyrocketed by 47700bps in 2024.
  • InMed Pharmaceuticals' Return on Equity (Quarter) stood at 1.34% in 2022, then plummeted by -197bps to 3.97% in 2023, then surged by 73bps to 1.08% in 2024, then skyrocketed by 40bps to 0.66% in 2025.
  • Its last three reported values are 0.66% in Q3 2025, 0.8% for Q2 2025, and 1.26% during Q1 2025.